Companies

Case Study:

Advanced Cell Diagnostics

“Summit made an impact even before our investment partnership began, making introductions, offering strategic guidance and providing hands-on operational support that helped us to raise our profile as a leader in precision medicine.”

Founded in 2006, Advanced Cell Diagnostics (ACD) quickly established itself as a leader in the field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine and life science research. With a rapidly growing product portfolio based on its proprietary RNAscope® technology, ACD sought an experienced life sciences investor to help expand the company’s go-to-market capability with a focus on international expansion and eCommerce enablement.

How Summit Helped

Summit led a Series C equity financing round in 2015

Introduced Dr. Ken Fong – founder of former Summit portfolio company Clontech – who became an advisor to ACD

Summit’s Peak Performance Group worked closely with management to help ACD optimize its sales force and develop the sales operations function to manage global scale

Advanced Cell Diagnostics has continued to build on its market and technology leadership position with its award-winning RNAscope technology. ACD products are used in thousands of leading academic and industrial labs, and in 2015 alone, ACD’s technology was cited in more than 500 peer-reviewed research publications. The company’s strong growth and innovative, transformative technology attracted the attention of strategic acquirer Bio-Techne Corporation (NASDAQ: TECH). The acquisition allowed Bio-Techne to enter the genomics market and to expand its presence in both research and clinical setting. Today, ACD operates as an independent subsidiary of Bio-Techne and is a world leader in RNA biomarker analysis for precision medicine.